LSBio logo with text
Products
Research Areas
COVID-19
Resources
Contact Us
Login
Quick Order
Cart Cart lightblue
Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order
Cart
How To Buy
Contact Us

Location

Corporate Headquarters

Vector Laboratories, Inc.
6737 Mowry Ave
Newark, CA 94560
United States

Telephone Numbers


Customer Service: (800) 227-6666 / (650) 697-3600


Contact Us


Additional Contact Details

Distributors
Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order

BIRC5 / Survivin

baculoviral IAP repeat containing 5

Multitasking protein that has dual roles in promoting cell proliferation and preventing apoptosis. Component of a chromosome passage protein complex (CPC) which is essential for chromosome alignment and segregation during mitosis and cytokinesis. Acts as an important regulator of the localization of this complex; directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organization of the center spindle by associating with polymerized microtubules. The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules. May counteract a default induction of apoptosis in G2/M phase. The acetylated form represses STAT3 transactivation of target gene promoters. May play a role in neoplasia. Inhibitor of CASP3 and CASP7. Isoform 2 and isoform 3 do not appear to play vital roles in mitosis. Isoform 3 shows a marked reduction in its anti-apoptotic effects when compared with the displayed wild-type isoform.

Gene Name: baculoviral IAP repeat containing 5
Family/Subfamily: Apoptosis
Synonyms: BIRC5, API4, Apoptosis inhibitor survivin, Apoptosis inhibitor 4, Survivin, Survivin variant 3 alpha, EPR-1, IAP4
Target Sequences: NM_001168 NP_001159.2 O15392

Publications (147)

1
INCENP is required for proper targeting of Survivin to the centromeres and the anaphase spindle during mitosis. Wheatley SP, Carvalho A, Vagnarelli P, Earnshaw WC. Current biology : CB. 2001 11:886-90. (ICC; Human) [PubMed:11516652]
2
Anti-apoptotic protein survivin plays a significant role in tubular morphogenesis of human coronary arteriolar endothelial cells by hypoxic preconditioning. Zhu L, Fukuda S, Cordis G, Das DK, Maulik N. FEBS letters. 2001 508:369-74. [PubMed:11728454]
3
CENP-A is phosphorylated by Aurora B kinase and plays an unexpected role in completion of cytokinesis. Zeitlin SG, Shelby RD, Sullivan KF. The Journal of cell biology. 2001 155:1147-57. [PubMed:11756469] [PMC:PMC2199334]
4
Quantitatively determined survivin expression levels are of prognostic value in human gliomas. Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ, Loeffler JS. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 20:1063-8. (WB; Human) [PubMed:11844831]
5
Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. Fortugno P, Wall NR, Giodini A, O'Connor DS, Plescia J, Padgett KM, Tognin S, Marchisio PC, Altieri DC. Journal of cell science. 2002 115:575-85. (ICC, WB, IP; Human) [PubMed:11861764]
6
Regulation of microtubule stability and mitotic progression by survivin. Giodini A, Kallio MJ, Wall NR, Gorbsky GJ, Tognin S, Marchisio PC, Symons M, Altieri DC. Cancer research. 2002 62:2462-7. (Human) [PubMed:11980633]
7
2-Methoxyestradiol induces mitochondria dependent apoptotic signaling in pancreatic cancer cells. Qanungo S, Basu A, Das M, Haldar S. Oncogene. 2002 21:4149-57. [PubMed:12037671]
8
Increased expression of survivin in gastric cancer patients and in first degree relatives. Yu J, Leung WK, Ebert MP, Ng EK, Go MY, Wang HB, Chung SC, Malfertheiner P, Sung JJ. British journal of cancer. 2002 87:91-7. (IHC-P; Human) [PubMed:12085263] [PMC:PMC2364284]
9
A p34(cdc2) survival checkpoint in cancer. O'Connor DS, Wall NR, Porter AC, Altieri DC. Cancer cell. 2002 2:43-54. [PubMed:12150824]
10
Inhibitor of apoptosis protein survivin regulates vascular injury. Blanc-Brude OP, Yu J, Simosa H, Conte MS, Sessa WC, Altieri DC. Nature medicine. 2002 8:987-94. [PubMed:12172543]
11
Differential subcellular localization of functionally divergent survivin splice variants. Mahotka C, Liebmann J, Wenzel M, Suschek CV, Schmitt M, Gabbert HE, Gerharz CD. Cell death and differentiation. 2002 9:1334-42. [PubMed:12478470]
12
Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Grabowski P, Khnel T, Mhr-Wilkenshoff F, Heine B, Stein H, Hpfner M, Germer CT, Scherbl H. British journal of cancer. 2003 88:115-9. [PubMed:12556969] [PMC:PMC2376783]
13
Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression. Allen SM, Florell SR, Hanks AN, Alexander A, Diedrich MJ, Altieri DC, Grossman D. Cancer research. 2003 63:567-72. [PubMed:12566297]
14
Differential activation of apoptosis regulatory pathways during monocytic vs granulocytic differentiation: a requirement for Bcl-X(L)and XIAP in the prolonged survival of monocytic cells. Miranda MB, Dyer KF, Grandis JR, Johnson DE. Leukemia. 2003 17:390-400. [PubMed:12592339]
15
Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia. Faderl S, Harris D, Van Q, Kantarjian HM, Talpaz M, Estrov Z. Blood. 2003 102:630-7. [PubMed:12663443]
16
Prognostic importance of survivin in breast cancer. Kennedy SM, O'Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Linehan R, Clynes M. British journal of cancer. 2003 88:1077-83. [PubMed:12671708] [PMC:PMC2376388]
17
The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. Hauf S, Cole RW, LaTerra S, Zimmer C, Schnapp G, Walter R, Heckel A, van Meel J, Rieder CL, Peters JM. The Journal of cell biology. 2003 161:281-94. [PubMed:12707311] [PMC:PMC2172906]
18
Apoptosis induction in renal cell carcinoma by TRAIL and gamma-radiation is impaired by deficient caspase-9 cleavage. Ramp U, Caliskan E, Mahotka C, Krieg A, Heikaus S, Gabbert HE, Gerharz CD. British journal of cancer. 2003 88:1800-7. [PubMed:12771998] [PMC:PMC2377130]
19
Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri DC. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 9:2683-92. [PubMed:12855648]
20
Loss of inhibitor of apoptosis proteins as a determinant of polyamine analog-induced apoptosis in human melanoma cells. Chen Y, Kramer DL, Li F, Porter CW. Oncogene. 2003 22:4964-72. [PubMed:12902979]
21
Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Honda R, Krner R, Nigg EA. Molecular biology of the cell. 2003 14:3325-41. [PubMed:12925766] [PMC:PMC181570]
22
Phosphorylation of mitotic kinesin-like protein 2 by polo-like kinase 1 is required for cytokinesis. Neef R, Preisinger C, Sutcliffe J, Kopajtich R, Nigg EA, Mayer TU, Barr FA. The Journal of cell biology. 2003 162:863-75. [PubMed:12939256] [PMC:PMC2172827]
23
Fibronectin protects prostate cancer cells from tumor necrosis factor-alpha-induced apoptosis via the AKT/survivin pathway. Fornaro M, Plescia J, Chheang S, Tallini G, Zhu YM, King M, Altieri DC, Languino LR. The Journal of biological chemistry. 2003 278:50402-11. [PubMed:14523021]
24
Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis. Beltrami E, Plescia J, Wilkinson JC, Duckett CS, Altieri DC. The Journal of biological chemistry. 2004 279:2077-84. [PubMed:14581472]
25
Nuclear expression of Survivin in paediatric ependymomas and choroid plexus tumours correlates with morphologic tumour grade. Altura RA, Olshefski RS, Jiang Y, Bou DR. British journal of cancer. 2003 89:1743-9. [PubMed:14583779] [PMC:PMC2394429]
26
COX-2-dependent stabilization of survivin in non-small cell lung cancer. Krysan K, Merchant FH, Zhu L, Dohadwala M, Luo J, Lin Y, Heuze-Vourc'h N, Pld M, Seligson D, Chia D, Goodglick L, Wang H, Strieter R, Sharma S, Dubinett S. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2004 18:206-8. [PubMed:14597555]
27
Promyelocytic leukemia protein 4 induces apoptosis by inhibition of survivin expression. Xu ZX, Zhao RX, Ding T, Tran TT, Zhang W, Pandolfi PP, Chang KS. The Journal of biological chemistry. 2004 279:1838-44. [PubMed:14597622]
28
Regulation of survivin function by Hsp90. Fortugno P, Beltrami E, Plescia J, Fontana J, Pradhan D, Marchisio PC, Sessa WC, Altieri DC. Proceedings of the National Academy of Sciences of the United States of America. 2003 100:13791-6. [PubMed:14614132] [PMC:PMC283500]
29
Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Chen JG, Yang CP, Cammer M, Horwitz SB. Cancer research. 2003 63:7891-9. [PubMed:14633718]
30
Roles of iNOS and nNOS in sepsis-induced pulmonary apoptosis. Rudkowski JC, Barreiro E, Harfouche R, Goldberg P, Kishta O, D'Orleans-Juste P, Labonte J, Lesur O, Hussain SN. American journal of physiology. Lung cellular and molecular physiology. 2004 286:L793-800. [PubMed:14660484]
31
Survivin expression in oral squamous cell carcinoma. Lo Muzio L, Pannone G, Staibano S, Mignogna MD, Rubini C, Mariggi MA, Procaccini M, Ferrari F, De Rosa G, Altieri DC. British journal of cancer. 2003 89:2244-8. [PubMed:14676801] [PMC:PMC2395285]
32
Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Liu T, Brouha B, Grossman D. Oncogene. 2004 23:39-48. [PubMed:14712209] [PMC:PMC2292403]
33
Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. Ku JH, Kwak C, Lee HS, Park HK, Lee E, Lee SE. The Journal of urology. 2004 171:631-5. [PubMed:14713775]
34
Differential expression of intracellular apoptotic signaling molecules in tumor and tumor-infiltrating lymphocytes during development of invasion and/or metastasis of gastric carcinoma. Koyama S. Digestive diseases and sciences. 2003 48:2290-300. [PubMed:14714615]
35
IL-11 protects human microvascular endothelium from alloinjury in vivo by induction of survivin expression. Kirkiles-Smith NC, Mahboubi K, Plescia J, McNiff JM, Karras J, Schechner JS, Altieri DC, Pober JS. Journal of immunology (Baltimore, Md. : 1950). 2004 172:1391-6. [PubMed:14734714]
36
Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Martinez A, Bellosillo B, Bosch F, Ferrer A, Marc S, Villamor N, Ott G, Montserrat E, Campo E, Colomer D. The American journal of pathology. 2004 164:501-10. [PubMed:14742256] [PMC:PMC1602245]
37
Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Ansell SM, Arendt BK, Grote DM, Jelinek DF, Novak AJ, Wellik LE, Remstein ED, Bennett CF, Fielding A. Leukemia. 2004 18:616-23. [PubMed:14749704]
38
Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Zha H, Raffeld M, Charboneau L, Pittaluga S, Kwak LW, Petricoin E, Liotta LA, Jaffe ES. Laboratory investigation; a journal of technical methods and pathology. 2004 84:235-44. [PubMed:14767488]
39
Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Komuro Y, Watanabe T, Tsurita G, Muto T, Nagawa H. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2004 17:264. [PubMed:14963460]
40
Survivin enhances Fas ligand expression via up-regulation of specificity protein 1-mediated gene transcription in colon cancer cells. Asanuma K, Tsuji N, Endoh T, Yagihashi A, Watanabe N. Journal of immunology (Baltimore, Md. : 1950). 2004 172:3922-9. [PubMed:15004200]
41
Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-F and Mad2, and chromosome congression. Johnson VL, Scott MI, Holt SV, Hussein D, Taylor SS. Journal of cell science. 2004 117:1577-89. [PubMed:15020684]
42
Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 22:1682-8. [PubMed:15117990]
43
Megakaryocytes express functional Aurora-B kinase in endomitosis. Geddis AE, Kaushansky K. Blood. 2004 104:1017-24. [PubMed:15130946]
44
Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Amin HM, McDonnell TJ, Ma Y, Lin Q, Fujio Y, Kunisada K, Leventaki V, Das P, Rassidakis GZ, Cutler C, Medeiros LJ, Lai R. Oncogene. 2004 23:5426-34. [PubMed:15184887]
45
Borealin: a novel chromosomal passenger required for stability of the bipolar mitotic spindle. Gassmann R, Carvalho A, Henzing AJ, Ruchaud S, Hudson DF, Honda R, Nigg EA, Gerloff DL, Earnshaw WC. The Journal of cell biology. 2004 166:179-91. [PubMed:15249581] [PMC:PMC2172304]
46
Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA, Robe P, Nestler U, Song Q, Loeffler J. Oncogene. 2004 23:7494-506. [PubMed:15326475]
47
Silibinin protects against photocarcinogenesis via modulation of cell cycle regulators, mitogen-activated protein kinases, and Akt signaling. Mallikarjuna G, Dhanalakshmi S, Singh RP, Agarwal C, Agarwal R. Cancer research. 2004 64:6349-56. [PubMed:15342425]
48
Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Chen JS, Liu JC, Shen L, Rau KM, Kuo HP, Li YM, Shi D, Lee YC, Chang KJ, Hung MC. Cancer gene therapy. 2004 11:740-7. [PubMed:15359286]
49
Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Krysan K, Dalwadi H, Sharma S, Pld M, Dubinett S. Cancer research. 2004 64:6359-62. [PubMed:15374938]
50
A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. Xu Y, Fang F, Ludewig G, Jones G, Jones D. DNA and cell biology. 2004 23:527-37. [PubMed:15383173]
51
A small C-terminal sequence of Aurora B is responsible for localization and function. Scrittori L, Skoufias DA, Hans F, Gerson V, Sassone-Corsi P, Dimitrov S, Margolis RL. Molecular biology of the cell. 2005 16:292-305. [PubMed:15509656] [PMC:PMC539173]
52
Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer. Vischioni B, van der Valk P, Span SW, Kruyt FA, Rodriguez JA, Giaccone G. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2004 15:1654-60. [PubMed:15520067]
53
Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer. Ryan B, O'Donovan N, Browne B, O'Shea C, Crown J, Hill AD, McDermott E, O'Higgins N, Duffy MJ. British journal of cancer. 2005 92:120-4. [PubMed:15611790] [PMC:PMC2361728]
54
Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. MacCallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella-Borradori A, Lane DP, Green SR. Cancer research. 2005 65:5399-407. [PubMed:15958589]
55
Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Asanuma H, Torigoe T, Kamiguchi K, Hirohashi Y, Ohmura T, Hirata K, Sato M, Sato N. Cancer research. 2005 65:11018-25. [PubMed:16322251]
56
TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo. Kim EY, Priatel JJ, Teh SJ, Teh HS. Journal of immunology (Baltimore, Md. : 1950). 2006 176:1026-35. [PubMed:16393990]
57
Nuclear expression of the antiapoptotic protein survivin in malignant melanoma. Ding Y, Prieto VG, Zhang PS, Rosenthal S, Smith KJ, Skelton HG, Diwan AH. Cancer. 2006 106:1123-9. [PubMed:16456815]
58
Survivin, a cancer target with an emerging role in normal adult tissues. Fukuda S, Pelus LM. Molecular cancer therapeutics. 2006 5:1087-98. [PubMed:16731740]
59
Regulation of survivin stability by the aryl hydrocarbon receptor-interacting protein. Kang BH, Altieri DC. The Journal of biological chemistry. 2006 281:24721-7. [PubMed:16807248]
60
Beta-catenin overexpression reduces myocardial infarct size through differential effects on cardiomyocytes and cardiac fibroblasts. Hahn JY, Cho HJ, Bae JW, Yuk HS, Kim KI, Park KW, Koo BK, Chae IH, Shin CS, Oh BH, Choi YS, Park YB, Kim HS. The Journal of biological chemistry. 2006 281:30979-89. [PubMed:16920707]
61
Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer. Yip KW, Shi W, Pintilie M, Martin JD, Mocanu JD, Wong D, MacMillan C, Gullane P, O'Sullivan B, Bastianutto C, Liu FF. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 12:5726-32. (IHC-P; Human) [PubMed:17020977]
62
Dissecting the role of endothelial SURVIVIN DeltaEx3 in angiogenesis. Caldas H, Fangusaro JR, Bou DR, Holloway MP, Altura RA. Blood. 2007 109:1479-89. [PubMed:17038538] [PMC:PMC1794050]
63
Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostate cancer LNCaP and 22Rv1 cells. Deep G, Oberlies NH, Kroll DJ, Agarwal R. Carcinogenesis. 2007 28:1533-42. [PubMed:17389612]
64
Tripin/hSgo2 recruits MCAK to the inner centromere to correct defective kinetochore attachments. Huang H, Feng J, Famulski J, Rattner JB, Liu ST, Kao GD, Muschel R, Chan GK, Yen TJ. The Journal of cell biology. 2007 177:413-24. [PubMed:17485487] [PMC:PMC2064832]
65
Survivin, a member of the inhibitor of apoptosis family, is induced by photodynamic therapy and is a target for improving treatment response. Ferrario A, Rucker N, Wong S, Luna M, Gomer CJ. Cancer research. 2007 67:4989-95. [PubMed:17510430]
66
Attenuation of apoptosis by chromogranin A-induced Akt and survivin pathways in prostate cancer cells. Gong J, Lee J, Akio H, Schlegel PN, Shen R. Endocrinology. 2007 148:4489-99. [PubMed:17584963]
67
Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Dohi T, Xia F, Altieri DC. Molecular cell. 2007 27:17-28. [PubMed:17612487] [PMC:PMC1986705]
68
Protective role of the inhibitor of apoptosis protein, survivin, in toxin-induced acute renal failure. Kindt N, Menzebach A, Van de Wouwer M, Betz I, De Vriese A, Conway EM. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2008 22:510-21. [PubMed:17804696]
69
Nitric oxide induces CD4+CD25+ Foxp3 regulatory T cells from CD4+CD25 T cells via p53, IL-2, and OX40. Niedbala W, Cai B, Liu H, Pitman N, Chang L, Liew FY. Proceedings of the National Academy of Sciences of the United States of America. 2007 104:15478-83. [PubMed:17875988] [PMC:PMC1978217]
70
The tumor gene survivin is highly expressed in adult renal tubular cells: implications for a pathophysiological role in the kidney. Lechler P, Wu X, Bernhardt W, Campean V, Gastiger S, Hackenbeck T, Klanke B, Weidemann A, Warnecke C, Amann K, Engehausen D, Willam C, Eckardt KU, Rdel F, Wiesener MS. The American journal of pathology. 2007 171:1483-98. (IHC-P) [PubMed:17982126] [PMC:PMC2043510]
71
Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells. Moiseeva EP, Almeida GM, Jones GD, Manson MM. Molecular cancer therapeutics. 2007 6:3071-9. [PubMed:18025290]
72
Mitosis persists in the absence of Cdk1 activity when proteolysis or protein phosphatase activity is suppressed. Skoufias DA, Indorato RL, Lacroix F, Panopoulos A, Margolis RL. The Journal of cell biology. 2007 179:671-85. [PubMed:18025303] [PMC:PMC2080905]
73
Nuclear survivin has reduced stability and is not cytoprotective. Connell CM, Colnaghi R, Wheatley SP. The Journal of biological chemistry. 2008 283:3289-96. [PubMed:18057009]
74
Hsp60 regulation of tumor cell apoptosis. Ghosh JC, Dohi T, Kang BH, Altieri DC. The Journal of biological chemistry. 2008 283:5188-94. [PubMed:18086682]
75
Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice. Tyagi A, Raina K, Singh RP, Gu M, Agarwal C, Harrison G, Glode LM, Agarwal R. Molecular cancer therapeutics. 2007 6:3248-55. [PubMed:18089718]
76
Mitochondrial targeting of adenomatous polyposis coli protein is stimulated by truncating cancer mutations: regulation of Bcl-2 and implications for cell survival. Brocardo M, Lei Y, Tighe A, Taylor SS, Mok MT, Henderson BR. The Journal of biological chemistry. 2008 283:5950-9. [PubMed:18160396]
77
Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin. Singh RP, Tyagi A, Sharma G, Mohan S, Agarwal R. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 14:300-8. [PubMed:18172282]
78
Monomeric recombinant peptide aptamers are required for efficient intracellular uptake and target inhibition. Borghouts C, Kunz C, Delis N, Groner B. Molecular cancer research : MCR. 2008 6:267-81. [PubMed:18314488]
79
Survival advantage of EBV-associated gastric carcinoma: survivin up-regulation by viral latent membrane protein 2A. Hino R, Uozaki H, Inoue Y, Shintani Y, Ushiku T, Sakatani T, Takada K, Fukayama M. Cancer research. 2008 68:1427-35. [PubMed:18316606]
80
Survivin determines cardiac function by controlling total cardiomyocyte number. Levkau B, Schfers M, Wohlschlaeger J, von Wnuck Lipinski K, Keul P, Hermann S, Kawaguchi N, Kirchhof P, Fabritz L, Stypmann J, Stegger L, Flgel U, Schrader J, Fischer JW, Fischer J, Hsieh P, Ou YL, Mehrhof F, Tiemann K, Ghanem A, Matus M, Neumann J, Heusc. Circulation. 2008 117:1583-93. [PubMed:18332262]
81
Tumor cell dependence on Ran-GTP-directed mitosis. Xia F, Lee CW, Altieri DC. Cancer research. 2008 68:1826-33. [PubMed:18339863]
82
Adeno-sh-beta-catenin abolishes ischemic preconditioning-mediated cardioprotection by downregulation of its target genes VEGF, Bcl-2, and survivin in ischemic rat myocardium. Thirunavukkarasu M, Han Z, Zhan L, Penumathsa SV, Menon VP, Maulik N. Antioxidants & redox signaling. 2008 10:1475-84. [PubMed:18407748] [PMC:PMC2932533]
83
Abnormal cytokinesis after X-irradiation in tumor cells that override the G2 DNA damage checkpoint. Huang H, Fletcher L, Beeharry N, Daniel R, Kao G, Yen TJ, Muschel RJ. Cancer research. 2008 68:3724-32. [PubMed:18483255]
84
Expression of the inhibitor of apoptosis protein family in multiple sclerosis reveals a potential immunomodulatory role during autoimmune mediated demyelination. Hebb AL, Moore CS, Bhan V, Campbell T, Fisk JD, Robertson HA, Thorne M, Lacasse E, Holcik M, Gillard J, Crocker SJ, Robertson GS. Multiple sclerosis (Houndmills, Basingstoke, England). 2008 14:577-94. [PubMed:18566024]
85
A survivin-ran complex regulates spindle formation in tumor cells. Xia F, Canovas PM, Guadagno TM, Altieri DC. Molecular and cellular biology. 2008 28:5299-311. [PubMed:18591255] [PMC:PMC2519733]
86
NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas. Engels K, Knauer SK, Loibl S, Fetz V, Harter P, Schweitzer A, Fisseler-Eckhoff A, Kommoss F, Hanker L, Nekljudova V, Hermanns I, Kleinert H, Mann W, du Bois A, Stauber RH. Cancer research. 2008 68:5159-66. [PubMed:18593915]
87
Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis. Lee CW, Raskett CM, Prudovsky I, Altieri DC. Cancer research. 2008 68:5273-81. [PubMed:18593928] [PMC:PMC2652573]
88
T-cell responses to survivin in cancer patients undergoing radiation therapy. Schaue D, Comin-Anduix B, Ribas A, Zhang L, Goodglick L, Sayre JW, Debucquoy A, Haustermans K, McBride WH. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 14:4883-90. [PubMed:18676762] [PMC:PMC2748652]
89
BKM1740, an acyl-tyrosine bisphosphonate amide derivative, inhibits the bone metastatic growth of human prostate cancer cells by inducing apoptosis. Seo SI, Gera L, Zhau HE, Qian WP, Iqbal S, Johnson NA, Zhang S, Zayzafoon M, Stewart J, Wang R, Chung LW, Wu D. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 14:6198-206. [PubMed:18829499]
90
Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia. Zhang L, Murray F, Zahno A, Kanter JR, Chou D, Suda R, Fenlon M, Rassenti L, Cottam H, Kipps TJ, Insel PA. Proceedings of the National Academy of Sciences of the United States of America. 2008 105:19532-7. [PubMed:19033455] [PMC:PMC2614795]
91
Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis. Dai Y, Liu M, Tang W, DeSano J, Burstein E, Davis M, Pienta K, Lawrence T, Xu L. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 14:7701-10. [PubMed:19047096] [PMC:PMC2605643]
92
Modulation of key regulators of mitosis linked to chromosomal instability is an early event in ochratoxin A carcinogenicity. Adler M, Mller K, Rached E, Dekant W, Mally A. Carcinogenesis. 2009 30:711-9. (IHC) [PubMed:19237604]
93
Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. Gould Rothberg BE, Bracken MB, Rimm DL. Journal of the National Cancer Institute. 2009 101:452-74. [PubMed:19318635] [PMC:PMC2720709]
94
Expression of the antiapoptosis gene Survivin predicts poor prognosis of stage III gastric adenocarcinoma. Song KY, Jung CK, Park WS, Park CH. Japanese journal of clinical oncology. 2009 39:290-6. [PubMed:19336448]
95
Endogenous tumor suppression mediated by PTEN involves survivin gene silencing. Guha M, Plescia J, Leav I, Li J, Languino LR, Altieri DC. Cancer research. 2009 69:4954-8. [PubMed:19470765] [PMC:PMC2718425]
96
3,3'-diindolylmethane enhances the efficacy of butyrate in colon cancer prevention through down-regulation of survivin. Bhatnagar N, Li X, Chen Y, Zhou X, Garrett SH, Guo B. Cancer prevention research (Philadelphia, Pa.). 2009 2:581-9. [PubMed:19470789] [PMC:PMC2901098]
97
ROC1/RBX1 E3 ubiquitin ligase silencing suppresses tumor cell growth via sequential induction of G2-M arrest, apoptosis, and senescence. Jia L, Soengas MS, Sun Y. Cancer research. 2009 69:4974-82. (WB) [PubMed:19509229] [PMC:PMC2744327]
98
Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Eberhard Y, McDermott SP, Wang X, Gronda M, Venugopal A, Wood TE, Hurren R, Datti A, Batey RA, Wrana J, Antholine WE, Dick JE, Dick J, Schimmer AD. Blood. 2009 114:3064-73. [PubMed:19589922]
99
Targeting the 90 kDa heat shock protein improves photodynamic therapy. Ferrario A, Gomer CJ. Cancer letters. 2010 289:188-94. (WB; Mouse) [PubMed:19733005] [PMC:PMC2829337]
100
TNFR2-deficient memory CD8 T cells provide superior protection against tumor cell growth. Kim EY, Teh SJ, Yang J, Chow MT, Teh HS. Journal of immunology (Baltimore, Md. : 1950). 2009 183:6051-7. [PubMed:19841176]
101
Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Shariat SF, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y, Isbarn H, Montorsi F, Jeldres C, Bastian PJ, Nielsen ME, Mller SC, Sagalowsky AI, Lotan Y. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 15:7012-9. [PubMed:19903782]
102
Oral administration of caffeine during voluntary exercise markedly decreases tissue fat and stimulates apoptosis and cyclin B1 in UVB-treated skin of hairless p53-knockout mice. Lou Y, Peng Q, Nolan B, Wagner GC, Lu Y. Carcinogenesis. 2010 31:671-8. [PubMed:19926639] [PMC:PMC2847084]
103
Immunohistochemical detection of survivin in canine lymphoma. Wimmershoff J, Polkinghorne A, Grest P, Schade B, Marchal T, Keller SM, Guscetti F. Journal of comparative pathology. 2010 142:311-22. (IHC; Dog) [PubMed:20116802]
104
Simultaneous gene silencing of Bcl-2, XIAP and Survivin re-sensitizes pancreatic cancer cells towards apoptosis. Rckert F, Samm N, Lehner AK, Saeger HD, Grtzmann R, Pilarsky C. BMC cancer. 2010 10:379. (WB; Human) [PubMed:20646298] [PMC:PMC2912871]
105
Survivin is released from cancer cells via exosomes. Khan S, Jutzy JM, Aspe JR, McGregor DW, Neidigh JW, Wall NR. Apoptosis : an international journal on programmed cell death. 2011 16:12-Jan. [PubMed:20717727] [PMC:PMC3174681]
106
Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity. Wang H, Holloway MP, Ma L, Cooper ZA, Riolo M, Samkari A, Elenitoba-Johnson KS, Chin YE, Altura RA. The Journal of biological chemistry. 2010 285:36129-37. [PubMed:20826784] [PMC:PMC2975235]
107
Differential regulation of TP73 isoforms by 1,25-dihydroxyvitamin D3 and survivin in human colon and breast carcinomas. Daz R, Gonzlez-Sancho JM, Soldevilla B, Silva J, Garca JM, Garca V, Pea C, Herrera M, Gmez I, Bonilla F, Domnguez G. Genes, chromosomes & cancer. 2010 49:1135-42. (WB; Human) [PubMed:20842728]
108
p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation. Xia M, Knezevic D, Vassilev LT. Oncogene. 2011 30:346-55. [PubMed:20871630]
109
Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Talbot DC, Ranson M, Davies J, Lahn M, Callies S, Andr V, Kadam S, Burgess M, Slapak C, Olsen AL, McHugh PJ, de Bono JS, Matthews J, Saleem A, Price P. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 16:6150-8. [PubMed:21041181]
110
Endothelial cells from humans and mice with polycystic kidney disease are characterized by polyploidy and chromosome segregation defects through survivin down-regulation. AbouAlaiwi WA, Ratnam S, Booth RL, Shah JV, Nauli SM. Human molecular genetics. 2011 20:354-67. (WB; Mouse) [PubMed:21041232] [PMC:PMC3005905]
111
Concomitant expression of HER2 and HIF-1alpha is a predictor of poor prognosis in uterine cervical carcinoma treated with concurrent chemoradiotherapy: prospective analysis (KGROG0501). Niibe Y, Watanabe J, Tsunoda S, Arai M, Arai T, Kawaguchi M, Matsuo K, Jobo T, Ono S, Numata A, Unno N, Hayakawa K. European journal of gynaecological oncology. 2010 31:491-6. [PubMed:21061787]
112
The prostaglandin E2 receptor, EP2, regulates survivin expression via an EGFR/STAT3 pathway in UVB-exposed mouse skin. Chun KS, Langenbach R. Molecular carcinogenesis. 2011 50:439-48. (WB; Mouse) [PubMed:21268125]
113
Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Finkelstein SE, Iclozan C, Bui MM, Cotter MJ, Ramakrishnan R, Ahmed J, Noyes DR, Cheong D, Gonzalez RJ, Heysek RV, Berman C, Lenox BC, Janssen W, Zager JS, Sondak VK, Letson GD, Antonia SJ, Gabrilovich DI. International journal of radiation oncology, biology, physics. 2012 82:924-32. [PubMed:21398051]
114
Garlic constituent diallyl trisulfide suppresses x-linked inhibitor of apoptosis protein in prostate cancer cells in culture and in vivo. Kim SH, Bommareddy A, Singh SV. Cancer prevention research (Philadelphia, Pa.). 2011 4:897-906. (IHC, WB; Mouse, Human) [PubMed:21411500] [PMC:PMC3107923]
115
The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines. Fossey SL, Bear MD, Lin J, Li C, Schwartz EB, Li PK, Fuchs JR, Fenger J, Kisseberth WC, London CA. BMC cancer. 2011 11:112. (WB; Dog, Human) [PubMed:21443800] [PMC:PMC3074561]
116
The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells in vitro. Lechler P, Renkawitz T, Campean V, Balakrishnan S, Tingart M, Grifka J, Schaumburger J. BMC cancer. 2011 11:120. [PubMed:21457573] [PMC:PMC3076263]
117
Rapamycin decreases survivin expression to induce NSCLC cell apoptosis under hypoxia through inhibiting HIF-1 induction. Chen B, Yuping S, Ni J. Molecular biology reports. 2012 39:185-91. (WB; Human) [PubMed:21567203]
118
Inactivation of chk2 and mus81 leads to impaired lymphocytes development, reduced genomic instability, and suppression of cancer. El Ghamrasni S, Pamidi A, Halaby MJ, Bohgaki M, Cardoso R, Li L, Venkatesan S, Sethu S, Hirao A, Mak TW, Hande MP, Hakem A, Hakem R. PLoS genetics. 2011 7:e1001385. [PubMed:21625617] [PMC:PMC3098187]
119
The oncofetal gene survivin promotes cell proliferation and survival in primary human osteoblastic cells. Lechler P, Schaumburger J, Kck FX, Balakrishnan S, Doukas S, Prantl L, Grifka J. Calcified tissue international. 2011 89:211-20. (ICC, WB; Human) [PubMed:21674243]
120
The oncofetal gene survivin is re-expressed in osteoarthritis and is required for chondrocyte proliferation in vitro. Lechler P, Balakrishnan S, Schaumburger J, Grssel S, Baier C, Grifka J, Straub RH, Renkawitz T. BMC musculoskeletal disorders. 2011 12:150. [PubMed:21729321] [PMC:PMC3141611]
121
Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain. Page BD, Fletcher S, Yue P, Li Z, Zhang X, Sharmeen S, Datti A, Wrana JL, Trudel S, Schimmer AD, Turkson J, Gunning PT. Bioorganic & medicinal chemistry letters. 2011 21:5605-9. [PubMed:21788134]
122
Asiatic acid inhibits pro-angiogenic effects of VEGF and human gliomas in endothelial cell culture models. Kavitha CV, Agarwal C, Agarwal R, Deep G. PloS one. 2011 6:e22745. [PubMed:21826202] [PMC:PMC3149605]
123
PSA regulates androgen receptor expression in prostate cancer cells. Saxena P, Trerotola M, Wang T, Li J, Sayeed A, Vanoudenhove J, Adams DS, Fitzgerald TJ, Altieri DC, Languino LR. The Prostate. 2012 72:769-76. (WB; Human) [PubMed:21956655] [PMC:PMC3404455]
124
Sustained proliferation and resistance to apoptosis after a cytotoxic insult are early alterations in rat colon carcinogenesis. Femia AP, Salvianti F, Luceri C, Dolara P, Salvadori M, Pinzani P, Caderni G. International journal of cancer. Journal international du cancer. 2012 131:529-36. (IHC; Rat) [PubMed:21976248]
125
Pigmented spindle cell nevus: clues for differentiating it from spindle cell malignant melanoma. A comprehensive survey including clinicopathologic, immunohistochemical, and FISH studies. Daz A, Valera A, Carrera C, Hakim S, Aguilera P, Garca A, Palou J, Puig S, Malvehy J, Alos L. The American journal of surgical pathology. 2011 35:1733-42. (IHC; Human) [PubMed:21997694]
126
Total Survivin and acetylated Survivin correlate with distinct molecular subtypes of breast cancer. Yakirevich E, Samkari A, Holloway MP, Lu S, Singh K, Yu J, Fenton MA, Altura RA. Human pathology. 2012 43:865-73. (IHC; Human) [PubMed:22055399]
127
Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients. Felisiak-Golabek A, Rembiszewska A, Rzepecka IK, Szafron L, Madry R, Murawska M, Napiorkowski T, Sobiczewski P, Osuch B, Kupryjanczyk J. Journal of ovarian research. 2011 4:20. [PubMed:22075440] [PMC:PMC3223127]
128
Phenethyl isothiocyanate suppresses inhibitor of apoptosis family protein expression in prostate cancer cells in culture and in vivo. Sakao K, Desineni S, Hahm ER, Singh SV. The Prostate. 2012 72:1104-16. (IHC, WB; Mouse, Human) [PubMed:22161756] [PMC:PMC3310272]
129
Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells. Francisco R, Prez-Perarnau A, Corts C, Gil J, Tauler A, Ambrosio S. Cancer letters. 2012 318:42-52. (WB; Human) [PubMed:22186300]
130
Histone deacetylase 6 (HDAC6) deacetylates survivin for its nuclear export in breast cancer. Riolo MT, Cooper ZA, Holloway MP, Cheng Y, Bianchi C, Yakirevich E, Ma L, Chin YE, Altura RA. The Journal of biological chemistry. 2012 287:10885-93. (WB; Human) [PubMed:22334690] [PMC:PMC3322878]
131
A novel role for survivin in erythroblast enucleation. Keerthivasan G, Liu H, Gump JM, Dowdy SF, Wickrema A, Crispino JD. Haematologica. 2012 97:1471-9. (ICC, WB; Mouse) [PubMed:22491741] [PMC:PMC3487547]
132
Oestrogen-induced genes in ductal carcinoma in situ: their comparison with invasive ductal carcinoma. Ebata A, Suzuki T, Takagi K, Miki Y, Onodera Y, Nakamura Y, Fujishima F, Ishida K, Watanabe M, Tamaki K, Ishida T, Ohuchi N, Sasano H. Endocrine-related cancer. 2012 19:485-96. (IHC; Human) [PubMed:22569827]
133
Chk2 phosphorylation of survivin-DeltaEx3 contributes to a DNA damage-sensing checkpoint in cancer. Lopergolo A, Tavecchio M, Lisanti S, Ghosh JC, Dohi T, Faversani A, Vaira V, Bosari S, Tanigawa N, Delia D, Kossenkov AV, Showe LC, Altieri DC. Cancer research. 2012 72:3251-9. (IHC; Human) [PubMed:22586065]
134
DNMT1: An emerging target in the treatment of invasive urinary bladder cancer. Wheatley SP, Carvalho A, Vagnarelli P, Earnshaw WC. Urologic oncology. 2012 (WB; Dog) [PubMed:22609058]
135
Nuclear survivin expression as a potentially useful tool for the diagnosis of canine cutaneous sebaceous lesions. Bongiovanni L, Suter MM, Malatesta D, Ordinelli A, Ciccarelli A, Romanucci M, Brenner O, Della Salda L. Veterinary dermatology. 2012 23:394-e73. (IHC; Dog) [PubMed:22681570]
136
Immunohistochemical investigation of cell cycle and apoptosis regulators (survivin, -catenin, p53, caspase 3) in canine appendicular osteosarcoma. Bongiovanni L, Mazzocchetti F, Malatesta D, Romanucci M, Ciccarelli A, Buracco P, De Maria R, Palmieri C, Martano M, Morello E, Maniscalco L, Della Salda L. BMC veterinary research. 2012 8:78. (IHC; Dog) [PubMed:22686277] [PMC:PMC3514374]
137
DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model. Zhang H, Wang Y, Liu C, Zhang L, Xia Q, Zhang Y, Wu J, Jiang C, Chen Y, Wu Y, Zha X, Yu X, Kong W. Cancer immunology, immunotherapy : CII. 2012 61:1857-67. (WB; Human) [PubMed:22706381]
138
Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell Lymphoma. Chao C, Silverberg MJ, Martnez-Maza O, Chi M, Abrams DI, Haque R, Zha HD, McGuire M, Xu L, Said J. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 18:4702-12. (IHC; Human) [PubMed:22711707]
139
Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Okamoto W, Okamoto I, Arao T, Kuwata K, Hatashita E, Yamaguchi H, Sakai K, Yanagihara K, Nishio K, Nakagawa K. Molecular cancer therapeutics. 2012 11:1557-64. (WB; Human) [PubMed:22729845]
140
Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion. Jiang C, Yi XP, Shen H, Li YX. World journal of gastroenterology : WJG. 2012 18:2956-65. (WB; Human) [PubMed:22736919] [PMC:PMC3380323]
141
Increased levels of survivin, via association with heat shock protein 90, in mucosal T cells from patients with Crohn's disease. de Souza HS, West GA, Rebert N, de la Motte C, Drazba J, Fiocchi C. Gastroenterology. 2012 143:1017-26.e9. (ICC, IHC, IP; Human) [PubMed:22749932] [PMC:PMC3578578]
142
Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Min L, Ji Y, Bakiri L, Qiu Z, Cen J, Chen X, Chen L, Scheuch H, Zheng H, Qin L, Zatloukal K, Hui L, Wagner EF. Nature cell biology. 2012 14:1203-11. (IHC, WB; Mouse, Human) [PubMed:23041974]
143
Haspin inhibitors reveal centromeric functions of Aurora B in chromosome segregation. Wang F, Ulyanova NP, Daum JR, Patnaik D, Kateneva AV, Gorbsky GJ, Higgins JM. The Journal of cell biology. 2012 199:251-68. [PubMed:23071152] [PMC:PMC3471242]
144
Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. Khan S, Jutzy JM, Valenzuela MM, Turay D, Aspe JR, Ashok A, Mirshahidi S, Mercola D, Lilly MB, Wall NR. PloS one. 2012 7:e46737. (WB; Human) [PubMed:23091600] [PMC:PMC3473028]
145
Functional characterization of novel mutations affecting survivin (BIRC5)-mediated therapy resistance in head and neck cancer patients. Knauer SK, Unruhe B, Karczewski S, Hecht R, Fetz V, Bier C, Friedl S, Wollenberg B, Pries R, Habtemichael N, Heinrich UR, Stauber RH. Human mutation. 2013 34:395-404. (IHC; Human) [PubMed:23161837]
146
Loss of Hfe leads to progression of tumor phenotype in primary retinal pigment epithelial cells. Gnana-Prakasam JP, Veeranan-Karmegam R, Coothankandaswamy V, Reddy SK, Martin PM, Thangaraju M, Smith SB, Ganapathy V. Investigative ophthalmology & visual science. 2013 54:63-71. [PubMed:23169885] [PMC:PMC3544423]
147
Effects of survivin on FVADT chemotherapy for refractory multiple myeloma. Yang H, Du X, Xi Y. Experimental and therapeutic medicine. 2016 12:771-776. (ICC; Human) [Full Text Article] [PubMed:27446274] [PMC:PMC4950835]
more

☰ Filters
Products
Antibodies (141)
Primary (141)
BIRC5 / Survivin (141)
Human (125)
Mouse (55)
Rat (40)
Cat (2)
Dog (2)
Gerbil (4)
Guinea pig (1)
Hamster (1)
Monkey (1)
IHC (58)
IHC-Fr (2)
IHC-P (43)
WB (115)
Flo (10)
ELISA (41)
ICC (27)
IF (42)
IP (14)
Peptide-ELISA (7)
RNAi (1)
rabbit (86)
mouse (53)
goat (2)
Product Group
IHCPlus (4)
PathPlus Neuro (2)
IgG (55)
IgG1 (19)
IgG1,k (11)
IgG2a,k (9)
monoclonal mc (55)
polyclonal pc (86)
102 (1)
1H5 (2)
2H5H2 (1)
32.1 (5)
4E2 (1)
5B10 (1)
60.11 (6)
8E2 (5)
OTI2D3 (2)
OTI2D9 (2)
OTI3G3 (2)
OTI6H5 (2)
AF488 Conjugated (1)
APC (3)
APC Conjugated (4)
Biotin Conjugated (13)
Carrier-free (4)
Concentrated (1)
Cy3 Conjugated (3)
Cy7 Conjugated (3)
DY488 Conjugated (5)
DY550 Conjugated (5)
DY650 Conjugated (5)
FITC Conjugated (7)
HRP Conjugated (6)
PE Conjugated (4)
Preservative Free (5)
Ready-to-Use (1)
Unconjugated (85)
aa1-142 (19)
aa1-140 (13)
pThr34 (8)
pSer20 (6)
aa3-19 (5)
aa57-67 (5)
pThr117 (4)
30-110 aa (2)
60-140 aa (2)
C-Terminus (2)
N-Terminus (2)
Ab-34 (1)
Asn111 (1)
aa11-60 (1)
aa121-142 (1)
aa123-142 (1)
aa154-165 (1)
aa86-135 (1)
p117 (1)
No (141)
BIRC5 / Survivin Antibody - IHC of paraffin-embedded cervical cancer tissues using BIRC5 mouse monoclonal antibody with DAB staining.
Select
BIRC5 / Survivin Antibody (clone 1H5) LS-C169452
BIRC5 / Survivin Mouse anti-Human Monoclonal (1H5) Antibody
Human
ELISA, Flo, IF, IHC, IHC-P, WB
Unconjugated
100 µl/$459
BIRC5 / Survivin Antibody - Anti-BIRC5 / Survivin antibody IHC of human adrenal. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody concentration 10 ug/ml.
Select
IHC-plus™ BIRC5 / Survivin Antibody (C-Terminus) LS-B2787
(4.0) Rating
BIRC5 / Survivin Rabbit anti-Human Polyclonal (C-Terminus) Antibody
Mouse, Human
IHC, IHC-P
Unconjugated
250 µl/$485
Select
BIRC5 / Survivin Antibody LS-C26302
BIRC5 / Survivin Mouse anti-Human Monoclonal Antibody
Mouse, Rat, Human
ELISA, ICC, IF, IHC, IHC-P, WB
Unconjugated
50 µl/$483; 100 µl/$688
BIRC5 / Survivin Antibody - Anti-Survivin antibody IHC of human tonsil. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody dilution 10 ug/ml.
Select
PathPlus™ BIRC5 / Survivin Antibody (aa86-135) LS-B8368
Neuroscience
(5.0) Rating
BIRC5 / Survivin Rabbit anti-Human Polyclonal (aa86-135) Antibody
Mouse, Rat, Human
IF, IHC, IHC-P, Peptide-ELISA, WB
Unconjugated
50 µl/$440
BIRC5 / Survivin Antibody - Anti-BIRC5 / Survivin antibody IHC of human ovarian cancer. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody concentration 5 ug/ml. This image was taken for the unconjugated form of this product. Other forms have not been tested.
Select
IHC-plus™ BIRC5 / Survivin Antibody (clone 60.11) LS-B499
(4.0) Rating
BIRC5 / Survivin Mouse anti-Human Monoclonal (60.11) Antibody
Mouse, Rat, Human
IHC, IHC-P, WB
Unconjugated
0.1 ml/$460
BIRC5 / Survivin Antibody - Anti-BIRC5 / Survivin antibody IHC of human ovarian cancer. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody concentration 5 ug/ml. This image was taken for the unconjugated form of this product. Other forms have not been tested.
Select
BIRC5 / Survivin Antibody (aa57-67, clone 60.11, Biotin) LS-C142262
BIRC5 / Survivin Mouse anti-Human Monoclonal (aa57-67) (Biotin) (60.11) Antibody
Mouse, Rat, Human
ICC, IF, IHC, IHC-P, WB
Biotin Conjugated
0.1 ml/$416
BIRC5 / Survivin Antibody - Anti-BIRC5 / Survivin antibody IHC of human ovarian cancer. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody concentration 5 ug/ml. This image was taken for the unconjugated form of this product. Other forms have not been tested.
Select
BIRC5 / Survivin Antibody (aa57-67, clone 60.11, DY550) LS-C142073
BIRC5 / Survivin Mouse anti-Human Monoclonal (aa57-67) (DY550) (60.11) Antibody
Mouse, Rat, Human
ICC, IF, IHC, IHC-P, WB
DY550 Conjugated
0.1 ml/$416
BIRC5 / Survivin Antibody - Anti-BIRC5 / Survivin antibody IHC of human ovarian cancer. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody concentration 5 ug/ml. This image was taken for the unconjugated form of this product. Other forms have not been tested.
Select
BIRC5 / Survivin Antibody (aa57-67, clone 60.11, DY650) LS-C142263
BIRC5 / Survivin Mouse anti-Human Monoclonal (aa57-67) (DY650) (60.11) Antibody
Mouse, Rat, Human
ICC, IF, IHC, IHC-P, WB
DY650 Conjugated
0.1 ml/$416
BIRC5 / Survivin Antibody - Anti-BIRC5 / Survivin antibody IHC of human ovarian cancer. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody concentration 5 ug/ml. This image was taken for the unconjugated form of this product. Other forms have not been tested.
Select
BIRC5 / Survivin Antibody (aa57-67, clone 60.11, DY488) LS-C142264
BIRC5 / Survivin Mouse anti-Human Monoclonal (aa57-67) (DY488) (60.11) Antibody
Mouse, Rat, Human
ICC, IF, IHC, IHC-P, WB
DY488 Conjugated
0.1 ml/$416
BIRC5 / Survivin Antibody - Western blot using survivin mouse monoclonal antibody against full-length survivin recombinant protein (1) and full-length survivin-GFP transfected Cos7 cell lysate (2).
Select
BIRC5 / Survivin Antibody (clone 2H5H2) LS-C41525
BIRC5 / Survivin Mouse anti-Human Monoclonal (2H5H2) Antibody
Human
ELISA, IHC, IHC-P, WB
Unconjugated
100 µl/$435
BIRC5 / Survivin Antibody - Anti-BIRC5 / Survivin antibody IHC of human tonsil. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody concentration 5 ug/ml.
Select
IHC-plus™ BIRC5 / Survivin Antibody LS-B189
(4.0) Rating
BIRC5 / Survivin Rabbit anti-Human Polyclonal Antibody
Human
ELISA, ICC, IF, IHC, IHC-P, WB
Unconjugated
0.05 mg/$460
Select
BIRC5 / Survivin Antibody (Preservative Free) LS-C149209
BIRC5 / Survivin Rabbit anti-Human Polyclonal (Preservative Free) Antibody
Human
ELISA
Unconjugated, Preservative Free
20 µg/$242; 100 µg/$304; 200 µg/$334; 500 µg/$452
BIRC5 / Survivin Antibody - IHC of Survivin in formalin-fixed, paraffin-embedded human prostate and breast cancer using Polyclonal Antibody to Survivin at 1:2000. A and A1, prostate cancer at low and high magnification, respectively. B and B1, breast cancer. B1 is a high magnification of an area of metastasis. Hematoxylin-Eosin counterstain.
Select
BIRC5 / Survivin Antibody LS-C148291
BIRC5 / Survivin Rabbit anti-Human Polyclonal Antibody
Mouse, Rat, Gerbil, Human
IHC, IHC-Fr, IHC-P, IP, WB
Unconjugated
50 µl/$386
BIRC5 / Survivin Antibody - Anti-BIRC5 / Survivin antibody IHC of human lung cancer. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody concentration 20 ug/ml. This image was taken for the unconjugated form of this product. Other forms have not been tested.
Select
IHC-plus™ BIRC5 / Survivin Antibody (clone 32.1) LS-B498
(4.0) Rating
BIRC5 / Survivin Mouse anti-Human Monoclonal (32.1) Antibody
Human
IHC, IHC-P, WB
Unconjugated
50 µl/$460
BIRC5 / Survivin Antibody - Immunohistochemistry: Survivin Antibody (8E2) - Analysis of Survivin in human breast cancer using DAB with hematoxylin counterstain. This image was taken for the unconjugated form of this product. Other forms have not been tested.
Select
BIRC5 / Survivin Antibody (clone 8E2) LS-C179997
BIRC5 / Survivin Mouse anti-Human Monoclonal (8E2) Antibody
Rat, Human
ICC, IHC, IHC-P
Unconjugated
0.1 ml/$386
Select
BIRC5 / Survivin Antibody (AF488) LS-C39342
BIRC5 / Survivin Rabbit anti-Human Monoclonal (AF488) Antibody
Mouse, Rat, Human
Flo, ICC, IF
AF488 Conjugated
100 µl/$640
BIRC5 / Survivin Antibody - Immunohistochemical analysis of Survivin staining in human colon cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with hematoxylin and mounted with DPX.
Select
BIRC5 / Survivin Antibody LS-C413593
BIRC5 / Survivin Mouse anti-Human Monoclonal Antibody
Rat, Human
IHC, IHC-P, WB
Unconjugated
100 µl/$321
BIRC5 / Survivin Antibody - Survivin Antibody in Immunohistochemistry (IHC)
Select
BIRC5 / Survivin Antibody (clone 1H5) LS-C759607
BIRC5 / Survivin Mouse anti-Human Monoclonal (1H5) Antibody
Human
Flo, ICC, IF, IHC, WB
Unconjugated
100 µg/$503
Select
BIRC5 / Survivin Antibody (N-Terminus) LS-C26305
BIRC5 / Survivin Mouse anti-Human Monoclonal (N-Terminus) Antibody
Human
ELISA, IP, WB
Unconjugated
100 µg/$786
BIRC5 / Survivin Antibody - Immunohistochemical staining of paraffin-embedded Human Kidney tissue using anti-BI mouse monoclonal antibody. (Dilution 1:50).
Select
BIRC5 / Survivin Antibody (clone OTI2D9) LS-C115263
BIRC5 / Survivin Mouse anti-Human Monoclonal (OTI2D9) Antibody
Flo, IF, IHC, IHC-P, WB
Unconjugated
100 µl/$434
BIRC5 / Survivin Antibody - Immunohistochemical staining of paraffin-embedded Human Kidney tissue using anti-BI mouse monoclonal antibody. (Dilution 1:50).
Select
BIRC5 / Survivin Antibody (clone OTI2D9, Carrier-free) LS-C797302
BIRC5 / Survivin Mouse anti-Human Monoclonal (Carrier-free) (OTI2D9) Antibody
Human
Flo, IF, IHC, WB
Unconjugated, Carrier-free
100 µg/$511
BIRC5 / Survivin Antibody - Immunohistochemistry of Survivin in mouse brain tissue with Survivin Antibodyat 5 µg/mL.
Select
BIRC5 / Survivin Antibody LS-C369
BIRC5 / Survivin Rabbit anti-Human Polyclonal Antibody
Mouse, Human
ELISA, ICC, IF, IHC, WB
Unconjugated
0.1 mg/$460
BIRC5 / Survivin Antibody - 1:100 staining human heart tissue by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.
Select
BIRC5 / Survivin Antibody (phospho-Thr117) LS-C800878
BIRC5 / Survivin Rabbit anti-Human Polyclonal (pThr117) Antibody
Mouse, Rat, Human
IF, IHC, Peptide-ELISA, WB
Unconjugated
100 µl/$379; 200 µl/$421
Select
BIRC5 / Survivin Antibody (aa3-19) LS-C89859
BIRC5 / Survivin Mouse anti-Human Monoclonal (aa3-19) Antibody
Human
ICC, IF, IHC, IHC-P, WB
Unconjugated
100 µl/$688
BIRC5 / Survivin Antibody - Immunofluorescence of monoclonal antibody to BIRC5 on HeLa cell . [antibody concentration 10 ug/ml]
Select
BIRC5 / Survivin Antibody (clone 5B10) LS-C196668
BIRC5 / Survivin Mouse anti-Human Monoclonal (5B10) Antibody
Human
ELISA, IF, IP, RNAi, WB
Unconjugated
100 µg/$423
Viewing 1-25 of 141 product results

(0) Selected Add Selected To Cart Compare Selected Clear Selected Top Of Search
Filtered By:
Products: Antibodies


If you do not find the reagent or information you require, please contact Customer.Support@LSBio.com to inquire about additional products in development.

PLEASE NOTE

For RESEARCH USE ONLY. Intended for use by laboratory professionals. Not intended for human diagnostic or therapeutic purposes.

The data on this page has been compiled from LifeSpan internal sources, the National Center for Biotechnology Information (NCBI), and The Universal Protein Resource (UniProt).

Family of Companies
Site Links Home All Antibodies How To Buy All Proteins Distributors All ELISA & Assay Kits Reviews PathPlus™ Antibodies
Follow LSBio View Cart Register or Login
Copyright © 2024 LifeSpan BioSciences, Inc - Privacy Policy
Contact Us

Vector Laboratories, Inc.
6737 Mowry Ave
Newark, CA 94560
United States

Tel: (800) 227-6666 / (650) 697-3600

To place an order:
customerservice@vectorlabs.com

For questions about orders:
Customer.Support@LSBio.com

For technical assistance:
Technical.Support@LSBio.com